Clinical Trials Logo

Neoplasms clinical trials

View clinical trials related to Neoplasms.

Filter by:

NCT ID: NCT06241456 Recruiting - Clinical trials for Advanced Solid Tumor

FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors

Start date: January 5, 2024
Phase: Phase 1
Study type: Interventional

This is a phase 1 study designed to evaluate the safety, tolerability, and antitumor activity of FT825 (also known as ONO-8250) with or without monoclonal antibody therapy following chemotherapy in participants with advanced human epidermal growth factor receptor 2 (HER2)-positive or other advanced solid tumors. The study will consist of a dose-escalation stage, followed by an expansion stage to further evaluate the safety and activity of FT825 in indication-specific cohorts.

NCT ID: NCT06240741 Recruiting - Clinical trials for Neuroendocrine Neoplasms

A Prospective, Open-label Study of [68Ga]Ga-DOTA-TATE in Patients With Neuroendocrine Neoplasms (NENs) and Healthy Volunteers in Japan

Start date: March 21, 2024
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the diagnostic performance of [68Ga]Ga-DOTA-TATE Positron Emission Tomography (PET)/Computerized Tomography (CT) imaging compared with conventional imaging (CIM) as standard of truth in patients with neuroendocrine neoplasms (NENs) and healthy volunteers (HVs). The data from this study will provide the evidence for diagnosis of [68Ga]Ga-DOTA-TATE PET/CT imaging in patient with NENs in Japan.

NCT ID: NCT06240728 Recruiting - Clinical trials for Metastatic Malignant Neoplasm

A Study of NPX887 for Participants With Solid Tumors Known to Express HHLA2/B7-H7

Start date: January 22, 2024
Phase: Phase 1
Study type: Interventional

NPX887 is a human, antagonistic immunoglobulin G1 (IgG1) monoclonal antibody targeting HHLA2 (B7-H7) that may potentiate an anti-tumor immune response. The goal of this first-in-human study is to learn whether NPX887 is safe and tolerable in participants whose cancers are known to express HHLA2 (B7-H7).The main questions it aims to answer are: - what is an appropriate dose to be given to participants? - are the side effects of treatment manageable? Participants who are treated will receive an intravenous (IV) infusion of NPX887 if their disease has not progressed, and be closely monitored by the treating physicians.

NCT ID: NCT06240546 Recruiting - Clinical trials for Advanced Solid Tumor

First-in-Human Study of LPM6690176 in Patients With Advanced Solid Tumors.

Start date: March 12, 2024
Phase: Phase 1
Study type: Interventional

This study is a phase 1, first-in-human, open-label, dose-escalation and dose-expansion study designed to evaluate the safety and tolerability, pharmacokinetics characteristics and preliminary anti-tumor activity of LPM6690176 capsules in patients with advanced solid tumors.

NCT ID: NCT06239623 Recruiting - Melanoma Clinical Trials

ERK Inhibitor JSI-1187 in Advanced Solid Tumors

Start date: April 2, 2022
Phase: Phase 1
Study type: Interventional

JSI-1187-101 phase 1 study

NCT ID: NCT06239298 Recruiting - Solid Tumor Clinical Trials

A Study of ZG005 Combined With Donafenib in Patients With Advanced Solid Tumor

Start date: May 10, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Multi-center, Open-labe, Phase I/II Study to evaluate the safety and tolerability of ZG005 Combined With Donafenib in Patients With Advanced Solid Tumor.

NCT ID: NCT06238687 Recruiting - Neoplasm Malignant Clinical Trials

A Study of STRO-002 in Chinese Adults With Epithelial Ovarian Cancer and Other Advanced Malignant Solid Tumors

Start date: November 8, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a multi-center, open-label, monotherapy dose escalation, PK bridging, and dose expansion Phase I/IIa study in Chinese adult subjects to evaluate the safety, tolerability, Pharmacokinetics (PK) profiles, immunogenicity, and preliminary efficacy of STRO-002 in patients with advanced malignant solid tumors.

NCT ID: NCT06238479 Recruiting - Prostate Cancer Clinical Trials

A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors

Start date: March 5, 2024
Phase: Phase 1
Study type: Interventional

The purpose of this study is to find out whether the study drug, LY4101174, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.

NCT ID: NCT06238401 Not yet recruiting - Clinical trials for Advanced Solid Tumors

Study of ACR246 in Advanced Solid Tumors

Start date: March 1, 2024
Phase: Phase 1
Study type: Interventional

The goal of the study is to evaluate the safety and tolerability of ACR246 in patients with advanced solid tumors, to determine the maximum tolerated dose (MTD) and Phase II recommended dose (RP2D) of ACR246.

NCT ID: NCT06238284 Not yet recruiting - Ovarian Cancer Clinical Trials

HER2 Expression in Gynecological Malignant Tumors in Chongqing Area of China

Start date: January 26, 2024
Phase:
Study type: Observational

This study aims to retrospectively analyze the HER2 expression of gynecological malignant tumors in Chongqing by immunohistochemical detection, and explore the correlation between HER2 level, therapy response and prognosis based on patient clinical information.